407(top 0.1%)
PR articles
48.3K(top 0.1%)
PR citations
89(top 0.1%)
PR h-index
93(top 0.1%)
h-index
477
documents
63.6K
doc citations
4.3K
citing journals
100
times ranked

Publications

427 peer-reviewed articles • 55,356 peer-reviewed citations • Sorted by year • Download PDF (PDF by citations)
Sort: Year | Citations
#ArticleIFCitationsLinks
1Utility of methylated DNA markers for the diagnosis of malignant biliary strictures
Hepatology, 2025, 81, 453-464
9.512Citations (PDF)
2Surveillance for Hepatocellular Carcinoma
Clinics in Liver Disease, 2025, 29, 17-31
1.60Citations (PDF)
3Genetic, Epigenetic, and Microenvironmental Drivers of Cholangiocarcinoma
American Journal of Pathology, 2025, 195, 362-377
2.814Citations (PDF)
4Early-Onset Gastrointestinal Cancers and Metabolic Risk Factors: Global Trends From the Global Burden of Disease Study 2021
Mayo Clinic Proceedings, 2025, 100, 1159-1171
2.014Citations (PDF)
5CLO25-087: Low Serum Pseudocholinesterase Level Predicts HCC Mortality As Accurately As the ALBI or MESIAH Score
Journal of the National Comprehensive Cancer Network: JNCCN, 2025, 23,
2.80Citations (PDF)
6Blood and tissue dysregulated bile acids and short-chain fatty acids in cholangiocarcinoma
JHEP Reports, 2025, 7, 101467
3.53Citations (PDF)
7Integrative review in PhD admissions: A case study of efficiently minimizing bias while maximizing the student narrative
PLoS ONE, 2025, 20, e0323426
1.50Citations (PDF)
8SerpinB3/4 Expression Is Associated with Poor Prognosis in Patients with Cholangiocarcinoma
Cancers, 2024, 16, 225
2.74Citations (PDF)
9Combined Antitumor Effect of the Serine Protease Urokinase Inhibitor Upamostat and the Sphingosine Kinase 2 Inhibitor Opaganib on Cholangiocarcinoma Patient-Derived Xenografts
Cancers, 2024, 16, 1050
2.73Citations (PDF)
10Metabolome-wide association identifies altered metabolites and metabolic pathways in the serum of patients with cholangiocarcinoma
JHEP Reports, 2024, 6, 101068
3.59Citations (PDF)
11Expression of tumor antigens within an oncolytic virus enhances the anti-tumor T cell response
Nature Communications, 2024, 15,
11.055Citations (PDF)
12Incidence and Long-Term Outcomes of Biliary Tract Cancers in Olmsted County, Minnesota from 1976 to 2018
Cancers, 2024, 16, 2720
2.76Citations (PDF)
13GALAD Score for the Diagnosis of Hepatocellular Carcinoma in Sub-Saharan Africa: A Validation Study in Ghanaian Patients
Cancer Research Communications, 2024, 4, 2653-2659
2.112Citations (PDF)
14Diagnostic Accuracy Performance of Fluorescence In Situ Hybridization (FISH) for Biliary Strictures: A Systematic Review and Meta-Analysis
Journal of Clinical Medicine, 2024, 13, 6457
1.86Citations (PDF)
15Global burden of liver cancer in males and females: Changing etiological basis and the growing contribution of NASH
Hepatology, 2023, 77, 1150-1163
9.5136Citations (PDF)
16Phase I Trial of a Therapeutic DNA Vaccine for Preventing Hepatocellular Carcinoma from Chronic Hepatitis C Virus (HCV) Infection
Cancer Prevention Research, 2023, 16, 163-173
1.219Citations (PDF)
17Human VH-based chimeric antigen receptor T cells targeting glypican 3 eliminate tumors in preclinical models of HCC
Hepatology Communications, 2023, 7, e0022-e0022
3.317Citations (PDF)
18Mixed Acinar Neuroendocrine Carcinoma of the Pancreas: Comparative Population-Based Epidemiology of a Rare and Fatal Malignancy in The United States
Cancers, 2023, 15, 840
2.73Citations (PDF)
19Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance
Nature Reviews Gastroenterology and Hepatology, 2023, 20, 462-480
31.144Citations (PDF)
20Analysis of N-linked Glycan Alterations in Tissue and Serum Reveals Promising Biomarkers for Intrahepatic Cholangiocarcinoma
Cancer Research Communications, 2023, 3, 383-394
2.112Citations (PDF)
21The NAMPT Inhibitor FK866 in Combination with Cisplatin Reduces Cholangiocarcinoma Cells Growth
Cells, 2023, 12, 775
3.419Citations (PDF)
22Evidence for Benefits of Early Treatment Initiation for Chronic Hepatitis B
Viruses, 2023, 15, 997
2.240Citations (PDF)
23Effectiveness of HCC surveillance programs using multitarget blood test: A modeling study
Hepatology Communications, 2023, 7,
3.36Citations (PDF)
24Non-Alcoholic Fatty Liver Disease and Liver Fibrosis in Persons with Type 2 Diabetes Mellitus in Ghana: A Study of Prevalence, Severity, and Contributing Factors Using Transient Elastography
Journal of Clinical Medicine, 2023, 12, 3741
1.87Citations (PDF)
25Opportunities to address gaps in early detection and improve outcomes of liver cancer
JNCI Cancer Spectrum, 2023, 7,
2.343Citations (PDF)
26Tu1551 COST-EFFECTIVENESS OF HEPATOCELLULAR CARCINOMA SURVEILLANCE PROGRAMS USING MULTI-TARGET BLOOD TEST
Gastroenterology, 2023, 164, S-1412
0.90Citations (PDF)
27Sa1004 THE EFFECT OF SOCIAL MEDIA USAGE ON COLORECTAL CANCER (CRC) SCREENING PRACTICES AMONG IMMIGRANT POPULATIONS IN THE UNITED STATES
Gastroenterology, 2023, 164, S-270
0.90Citations (PDF)
28Mendelian randomization in hepatology: A review of principles, opportunities, and challenges
Hepatology, 2023, 81, 1836-1846
9.519Citations (PDF)
29Therapeutic Underuse and Delay in Hepatocellular Carcinoma: Prevalence, Associated Factors, and Clinical Impact
Hepatology Communications, 2022, 6, 223-236
3.322Citations (PDF)
30Synergistic combination of cytotoxic chemotherapy and cyclin‐dependent kinase 4/6 inhibitors in biliary tract cancers
Hepatology, 2022, 75, 43-58
9.515Citations (PDF)
31Decreasing Trend of Serum α-Fetoprotein Level in Hepatocellular Carcinoma
Clinical Gastroenterology and Hepatology, 2022, 20, 1177-1179.e4
5.329Citations (PDF)
32Validation of a Novel Multitarget Blood Test Shows High Sensitivity to Detect Early Stage Hepatocellular Carcinoma
Clinical Gastroenterology and Hepatology, 2022, 20, 173-182.e7
5.3149Citations (PDF)
33Morphological heterogeneity in beta-catenin–mutated hepatocellular carcinomas: implications for tumor molecular classification
Human Pathology, 2022, 119, 15-27
1.724Citations (PDF)
34PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and 68Ga‐PSMA‐11 PET Using Cyclotron‐Produced 68Ga
Hepatology Communications, 2022, 6, 1172-1185
3.345Citations (PDF)
35Impact of trimodality sampling on detection of malignant biliary strictures compared with patients with primary sclerosing cholangitis
Gastrointestinal Endoscopy, 2022, 95, 884-892
1.427Citations (PDF)
36Aspirin, Statins, Non-aspirin NSAIDs, Metformin, and the Risk of Biliary Cancer: A Swedish Population-Based Cohort Study
Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 804-810
0.615Citations (PDF)
37Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications
Expert Opinion on Therapeutic Targets, 2022, 26, 79-92
2.97Citations (PDF)
38Prognostic utility of systemic inflammatory markers and chronic hepatitis C virus infection status in hepatocellular carcinoma patients treated with local ablation
BMC Cancer, 2022, 22,
2.18Citations (PDF)
39Consensus subtypes of hepatocellular carcinoma associated with clinical outcomes and genomic phenotypes
Hepatology, 2022, 76, 1634-1648
9.527Citations (PDF)
40Large Hepatic Adenomas and Hepatic Adenomatosis: A Multicenter Study of Risk Factors, Interventions, and Complications
American Journal of Gastroenterology, 2022, 117, 1089-1096
0.610Citations (PDF)
41Association of metabolic health phenotypes, obesity, and hepatocellular carcinoma risk
Digestive and Liver Disease, 2022, 54, 964-972
1.925Citations (PDF)
42Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States
Hepatology, 2022, 76, 1649-1659
9.536Citations (PDF)
43Potential Role of Inflammation-Promoting Biliary Microbiome in Primary Sclerosing Cholangitis and Cholangiocarcinoma
Cancers, 2022, 14, 2120
2.730Citations (PDF)
44RNA Therapeutic Options to Manage Aberrant Signaling Pathways in Hepatocellular Carcinoma: Dream or Reality?
Frontiers in Oncology, 2022, 12,
1.710Citations (PDF)
45Su1336: TREATMENT INITIATION AND OUTCOMES OF AFRICAN AMERICANS AND NON-AFRICAN AMERICANS WITH CHRONIC HEPATITIS B VIRUS (HBV) INFECTION
Gastroenterology, 2022, 162, S-1186
0.90Citations (PDF)
46EP1203: ASSOCIATION OF METABOLIC HEALTH PHENOTYPES AND HEPATOCELLULAR CARCINOMA RISK
Gastroenterology, 2022, 162, S-1283
0.90Citations (PDF)
47Unmet Needs in Oncology Clinical Research and Treatment in Africa: Focus on Ghana
Oncologist, 2022, 27, 760-767
2.417Citations (PDF)
48Evaluating the Significance of Pancreatobiliary Fluorescence In Situ Hybridization Polysomy on Prognosis in De Novo Cholangiocarcinoma
Clinical and Translational Gastroenterology, 2022, 13, e00523
1.71Citations (PDF)
49Gaps in hepatocellular carcinoma surveillance in a United States cohort of insured patients with cirrhosis
Current Medical Research and Opinion, 2022, 38, 2163-2173
1.418Citations (PDF)
50Mortality burden due to liver cirrhosis and hepatocellular carcinoma in Ghana; prevalence of risk factors and predictors of poor in-hospital survival
PLoS ONE, 2022, 17, e0274544
1.525Citations (PDF)
51Gaps in hepatocellular carcinoma surveillance among insured patients with hepatitis B infection without cirrhosis in the United States
Hepatology Communications, 2022, 6, 3443-3456
3.310Citations (PDF)
52Establishment and Characterization of a New Human Intrahepatic Cholangiocarcinoma Cell Line LIV27
Cancers, 2022, 14, 5080
2.71Citations (PDF)
53A Novel Blood-Based Panel of Methylated DNA and Protein Markers for Detection of Early-Stage Hepatocellular Carcinoma
Clinical Gastroenterology and Hepatology, 2021, 19, 2597-2605.e4
5.3123Citations (PDF)
54Genetics of Hepatocellular Carcinoma: Approaches to Explore Molecular Diversity
Hepatology, 2021, 73, 14-26
9.585Citations (PDF)
55Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference
Hepatology, 2021, 73, 158-191
9.5374Citations (PDF)
56Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy
Hepatology, 2021, 73, 2124-2140
9.540Citations (PDF)
57Apobec1 complementation factor overexpression promotes hepatic steatosis, fibrosis, and hepatocellular cancer
Journal of Clinical Investigation, 2021, 131,
6.855Citations (PDF)
58Prognostic Significance of Neutrophil to Lymphocyte Ratio Dynamics in Patients with Hepatocellular Carcinoma Treated with Radioembolization Using Glass Microspheres
European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2624-2634
3.719Citations (PDF)
59Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling
Cell Reports, 2021, 34, 108765
4.444Citations (PDF)
60Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy
Nature Communications, 2021, 12,
11.029Citations (PDF)
61Aspirin and Statin Use and the Risk of Gallbladder Cancer
Cancers, 2021, 13, 1186
2.77Citations (PDF)
62Elevated rates of horizontal gene transfer in the industrialized human microbiome
Cell, 2021, 184, 2053-2067.e18
23.8349Citations (PDF)
63Differential characteristics and outcomes of Asian and non‐Asian patients with HBV‐related hepatocellular carcinoma
Liver International, 2021, 41, 1922-1932
3.128Citations (PDF)
64DNA Methylation Markers for Detection of Cholangiocarcinoma: Discovery, Validation, and Clinical Testing in Biliary Brushings and Plasma
Hepatology Communications, 2021, 5, 1448-1459
3.334Citations (PDF)
65BALAD and BALAD-2 predict survival of hepatocellular carcinoma patients: a North American cohort study
Hpb, 2021, 23, 762-769
0.220Citations (PDF)
66Fr386 SCREENING FOR NEW THERAPEUTIC AGENTS FOR CHOLANGIOCARCINOMA
Gastroenterology, 2021, 160, S-806
0.90Citations (PDF)
67Sulfatase 2 (SULF2) Monoclonal Antibody 5D5 Suppresses Human Cholangiocarcinoma Xenograft Growth Through Regulation of a SULF2–Platelet‐Derived Growth Factor Receptor Beta–Yes‐Associated Protein Signaling Axis
Hepatology, 2021, 74, 1411-1428
9.522Citations (PDF)
68Hepatitis B Screening of At-Risk Immigrants Seen at Primary Care Clinics: A Quality Improvement Project
Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021, 5, 635-644
2.35Citations (PDF)
69Distinct Patterns of HBV Integration and TERT Alterations between in Tumor and Non-Tumor Tissue in Patients with Hepatocellular Carcinoma
International Journal of Molecular Sciences, 2021, 22, 7056
3.231Citations (PDF)
70Using cell-free DNA for HCC surveillance and prognosis
JHEP Reports, 2021, 3, 100304
3.546Citations (PDF)
71Histone Deacetylase Sirtuin 1 Promotes Loss of Primary Cilia in Cholangiocarcinoma
Hepatology, 2021, 74, 3235-3248
9.518Citations (PDF)
72Comparison of Clinical Features and Outcomes Between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States
Hepatology, 2021, 74, 2622-2632
9.562Citations (PDF)
73Exogene: A performant workflow for detecting viral integrations from paired-end next-generation sequencing data
PLoS ONE, 2021, 16, e0250915
1.56Citations (PDF)
74Sulfatase-2 Regulates Liver Fibrosis through the TGF-β Signaling Pathway
Cancers, 2021, 13, 5279
2.716Citations (PDF)
75Direct-Acting Antiviral Therapy in Liver Transplant Patients With Hepatocellular Carcinoma and Hepatitis C
Transplantation Direct, 2021, 7, e635
1.310Citations (PDF)
76Diabetes Is Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Cirrhosis From Nonalcoholic Fatty Liver Disease
Hepatology, 2020, 71, 907-916
9.5192Citations (PDF)
77Type 3 Inositol 1,4,5‐Trisphosphate Receptor Is Increased and Enhances Malignant Properties in Cholangiocarcinoma
Hepatology, 2020, 71, 583-599
9.561Citations (PDF)
78Independent and Joint Use of Statins and Metformin by Elderly Patients With Diabetes and Overall Survival Following HCC Diagnosis
Journal of Clinical Gastroenterology, 2020, 54, 468-476
1.314Citations (PDF)
79Endoscopic Ultrasound/Fine Needle Aspiration Is Effective for Lymph Node Staging in Patients With Cholangiocarcinoma
Hepatology, 2020, 72, 940-948
9.566Citations (PDF)
80Knockout of sulfatase 2 is associated with decreased steatohepatitis and fibrosis in a mouse model of nonalcoholic fatty liver disease
American Journal of Physiology - Renal Physiology, 2020, 319, G333-G344
1.812Citations (PDF)
81Mo1415 PROGNOSTIC SIGNIFICANCE OF NEUTROPHIL-TO-LYMPHOCYTE AND LYMPHOCYTE-TO-MONOCYTE RATIOS IN PATIENTS UNDERGOING TRANSARTERIAL CHEMOEMBOLIZATION FOR HEPATOCELLULAR CARCINOMA
Gastroenterology, 2020, 158, S-1401
0.92Citations (PDF)
82Mo1419 HEPATOCELLULAR CARCINOMA MORPHOLOGICAL AND CLINICAL CHARACTERISTICS AND PATIENT OUTCOME
Gastroenterology, 2020, 158, S-1403
0.90Citations (PDF)
83Sa1511 FORECASTING HEPATITIS-RELATED LIVER DISEASE AMONG MIGRANTS TO SCANDINAVIA: ESTIMATING FUTURE DISEASE BURDENS IN FIVE NATIONS
Gastroenterology, 2020, 158, S-1316
0.91Citations (PDF)
84Sa1517 ESTIMATING THE IMPACT OF UNDOCUMENTED IMMIGRATION ON HEPATITIS B AND C PREVALENCE IN 41 U.S. STATES
Gastroenterology, 2020, 158, S-1318
0.90Citations (PDF)
85Lymphocyte to monocyte ratio-based nomogram for predicting outcomes of hepatocellular carcinoma treated with sorafenib
Hepatology International, 2020, 14, 776-787
3.220Citations (PDF)
86Mo1403 ASSOCIATIONS OF PANCREATOBILIARY FISH ASSAY GENETIC ABERRATIONS WITH CLINICAL CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH PERIHILAR CHOLANGIOCARCINOMA
Gastroenterology, 2020, 158, S-1395-S-1396
0.90Citations (PDF)
87Guidelines for Management of Urgent Symptoms in Patients with Cholangiocarcinoma and Biliary Stents or Catheters Using the Modified RAND/UCLA Delphi Process
Cancers, 2020, 12, 2375
2.72Citations (PDF)
88Quality of Care in Patients With Cirrhosis: Trends in Recommended Adult Vaccination Coverage
Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2020, 4, 667-682
2.36Citations (PDF)
89Characteristics of Patients With Chronic Hepatitis B Virus Infection With Genotype E Predominance in Burkina Faso
Hepatology Communications, 2020, 4, 1781-1792
3.314Citations (PDF)
90Su1004 ESTIMATING THE IMPACT OF ASYLUM-SEEKERS ON HEPATITIS ELIMINATION IN CANADA
Gastroenterology, 2020, 158, S-494
0.90Citations (PDF)
91The efficacy, safety, and predictors of outcomes of transarterial radioembolization for hepatocellular carcinoma: a retrospective study
Expert Review of Gastroenterology and Hepatology, 2020, 14, 619-629
1.79Citations (PDF)
92Biliary tract cancer patient-derived xenografts: Surgeon impact on individualized medicine
JHEP Reports, 2020, 2, 100068
3.524Citations (PDF)
93Knowledge, Attitudes, and Behaviors of Viral Hepatitis Among Recent African Immigrants in the United States: A Community Based Participatory Research Qualitative Study
Frontiers in Public Health, 2020, 8,
1.925Citations (PDF)
94Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma
Journal of Hepatology, 2020, 73, 315-327
7.4298Citations (PDF)
95Therapeutic Rationale to Target Highly Expressed Aurora kinase A Conferring Poor Prognosis in Cholangiocarcinoma
Journal of Cancer, 2020, 11, 2241-2251
1.73Citations (PDF)
96PKCλ/ι Loss Induces Autophagy, Oxidative Phosphorylation, and NRF2 to Promote Liver Cancer Progression
Cancer Cell, 2020, 38, 247-262.e11
28.7133Citations (PDF)
97Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Nature Reviews Gastroenterology and Hepatology, 2020, 17, 557-588
31.12,255Citations (PDF)
98The extracellular sulfatase SULF2 promotes liver tumorigenesis by stimulating assembly of a promoter-looping GLI1-STAT3 transcriptional complex
Journal of Biological Chemistry, 2020, 295, 2698-2712
1.313Citations (PDF)
99Effect of Statins on the Risk of Extrahepatic Cholangiocarcinoma
Hepatology, 2020, 72, 1298-1309
9.521Citations (PDF)
100One‐carbon metabolism‐related micronutrients intake and risk for hepatocellular carcinoma: A prospective cohort study
International Journal of Cancer, 2020, 147, 2075-2090
2.822Citations (PDF)
1011068. Large-Scale Migration and the Changing Viral Hepatitis Prevalences in North America: A modeling approach
Open Forum Infectious Diseases, 2020, 7, S563-S563
0.70Citations (PDF)
102A global view of hepatocellular carcinoma: trends, risk, prevention and management
Nature Reviews Gastroenterology and Hepatology, 2019, 16, 589-604
31.13,839Citations (PDF)
103Single-Dose Neoadjuvant AKT Pathway Inhibitor Reduces Growth of Hepatocellular Carcinoma after Laser Thermal Ablation in Small-Animal Model
Radiology, 2019, 292, 752-759
7.07Citations (PDF)
104TLX3 repressed SNAI1-induced epithelial-mesenchymal transition by directly constraining STAT3 phosphorylation and functionally sensitized 5-FU chemotherapy in hepatocellular carcinoma
International Journal of Biological Sciences, 2019, 15, 1696-1711
6.212Citations (PDF)
105DNA methylation of individual repetitive elements in hepatitis C virus infection-induced hepatocellular carcinoma
Clinical Epigenetics, 2019, 11,
3.139Citations (PDF)
106Genome-wide discovery and validation of diagnostic DNA methylation-based biomarkers for hepatocellular cancer detection in circulating cell free DNA
Theranostics, 2019, 9, 7239-7250
8.187Citations (PDF)
107Induction of Lysosome‐associated Protein Transmembrane 4 Beta via Sulfatase 2 Enhances Autophagic Flux in Liver Cancer Cells
Hepatology Communications, 2019, 3, 1520-1543
3.35Citations (PDF)
108Prognostic subclass of intrahepatic cholangiocarcinoma by integrative molecular–clinical analysis and potential targeted approach
Hepatology International, 2019, 13, 490-500
3.273Citations (PDF)
109Ccne1 Overexpression Causes Chromosome Instability in Liver Cells and Liver Tumor Development in Mice
Gastroenterology, 2019, 157, 210-226.e12
0.966Citations (PDF)
110Distinct phenotype and function of circulating Vδ1+ and Vδ2+ γδT-cells in acute and chronic hepatitis B
PLoS Pathogens, 2019, 15, e1007715
2.928Citations (PDF)
111Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis
European Journal of Surgical Oncology, 2019, 45, 1432-1438
1.5104Citations (PDF)
112Prognostic Subclasses of Intrahepatic Cholangiocarcinoma by Integrative Molecular-Clinical Analysis and Potential Targeted Approach
Hpb, 2019, 21, S207
0.20Citations (PDF)
113Role of Killer cell immunoglobulin-like receptors (KIR) genes in stages of HIV-1 infection among patients from Burkina Faso
Biomolecular Concepts, 2019, 10, 226-236
1.614Citations (PDF)
114Hepatocellular Carcinoma Detection by Plasma Methylated DNA: Discovery, Phase I Pilot, and Phase II Clinical Validation
Hepatology, 2019, 69, 1180-1192
9.5195Citations (PDF)
115Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy
Gastroenterology, 2019, 156, 492-509
0.9193Citations (PDF)
116GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score
Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 531-538
0.6211Citations (PDF)
117Association between treatment facility volume, therapy types and overall survival in patients with intrahepatic cholangiocarcinoma
Hpb, 2019, 21, 379-386
0.216Citations (PDF)
118Rationale and design of the Hepatocellular carcinoma Early Detection Strategy study: A multi-center longitudinal initiative of the National Cancer Institute’s Early Detection Research Network
Contemporary Clinical Trials, 2019, 76, 49-54
1.127Citations (PDF)
119Preclinical In Vitro and In Vivo Evidence of an Antitumor Effect of CX-4945, a Casein Kinase II Inhibitor, in Cholangiocarcinoma
Translational Oncology, 2019, 12, 143-153
2.839Citations (PDF)
120The incidence rates and survival of gallbladder cancer in the USA
European Journal of Cancer Prevention, 2019, 28, 1-9
1.350Citations (PDF)
121An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
Cell, 2018, 173, 400-416.e11
23.83,486Citations (PDF)
122Comprehensive Characterization of Cancer Driver Genes and Mutations
Cell, 2018, 173, 371-385.e18
23.82,168Citations (PDF)
123Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer
Cell, 2018, 173, 291-304.e6
23.82,492Citations (PDF)
124A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples
Cell, 2018, 173, 386-399.e12
23.8298Citations (PDF)
125Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics
Cell, 2018, 173, 305-320.e10
23.8381Citations (PDF)
126Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation
Cell, 2018, 173, 338-354.e15
23.82,076Citations (PDF)
127Oncogenic Signaling Pathways in The Cancer Genome Atlas
Cell, 2018, 173, 321-337.e10
23.83,051Citations (PDF)
128Pathogenic Germline Variants in 10,389 Adult Cancers
Cell, 2018, 173, 355-370.e14
23.8831Citations (PDF)
129Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types
Cell Reports, 2018, 23, 282-296.e4
4.4441Citations (PDF)
130Driver Fusions and Their Implications in the Development and Treatment of Human Cancers
Cell Reports, 2018, 23, 227-238.e3
4.4596Citations (PDF)
131Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas
Cell Reports, 2018, 23, 194-212.e6
4.4321Citations (PDF)
132Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context
Cell Reports, 2018, 23, 297-312.e12
4.4243Citations (PDF)
133The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma
Cell Reports, 2018, 23, 313-326.e5
4.4733Citations (PDF)
134Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images
Cell Reports, 2018, 23, 181-193.e7
4.4990Citations (PDF)
135The Immune Landscape of Cancer
Immunity, 2018, 48, 812-830.e14
16.65,243Citations (PDF)
136Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
Hepatology, 2018, 68, 723-750
9.54,241Citations (PDF)
137Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas
Cell Reports, 2018, 23, 172-180.e3
4.4152Citations (PDF)
138Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types
Cell Reports, 2018, 23, 213-226.e3
4.4114Citations (PDF)
139Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas
Cell Reports, 2018, 23, 239-254.e6
4.41,077Citations (PDF)
140Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers
Cell Reports, 2018, 23, 255-269.e4
4.4291Citations (PDF)
141Systematic Analysis of Splice-Site-Creating Mutations in Cancer
Cell Reports, 2018, 23, 270-281.e3
4.4235Citations (PDF)
142Hepatic stellate cell–derived platelet‐derived growth factor receptor‐alpha‐enriched extracellular vesicles promote liver fibrosis in mice through SHP2
Hepatology, 2018, 68, 333-348
9.5106Citations (PDF)
143Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma
Hepatology, 2018, 68, 949-963
9.5128Citations (PDF)
144Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines
Cell Systems, 2018, 6, 271-281.e7
3.7843Citations (PDF)
145Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas
Cell Systems, 2018, 6, 282-300.e2
3.7425Citations (PDF)
146lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer
Cancer Cell, 2018, 33, 706-720.e9
28.7460Citations (PDF)
147Genomic and Functional Approaches to Understanding Cancer Aneuploidy
Cancer Cell, 2018, 33, 676-689.e3
28.71,087Citations (PDF)
148Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas
Cancer Cell, 2018, 33, 721-735.e8
28.7524Citations (PDF)
149A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers
Cancer Cell, 2018, 33, 690-705.e9
28.7627Citations (PDF)
150Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study
The Lancet Gastroenterology and Hepatology, 2018, 3, 383-403
14.91,529Citations (PDF)
151Vascularized appendicular lymph node transfer for treatment of extremity lymphedema: A case report
Microsurgery, 2018, 38, 553-557
0.814Citations (PDF)
152Hepatocellular carcinoma in South America: Evaluation of risk factors, demographics and therapy
Liver International, 2018, 38, 136-143
3.178Citations (PDF)
153Heat stress induced, ligand-independent MET and EGFR signalling in hepatocellular carcinoma
International Journal of Hyperthermia, 2018, 34, 812-823
1.519Citations (PDF)
154Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis
Hepatology, 2018, 68, 78-88
9.556Citations (PDF)
155More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma
Liver International, 2018, 38, 895-902
3.131Citations (PDF)
156Imaging for the diagnosis of hepatocellular carcinoma: A systematic review and meta‐analysis
Hepatology, 2018, 67, 401-421
9.5453Citations (PDF)
157Barriers in Hepatitis C Treatment in Somali Patients in the Direct Acting Antiviral Therapy Era
Journal of the National Medical Association, 2018, 110, 556-559
0.43Citations (PDF)
158A SEER-based multi-ethnic picture of advanced intrahepatic cholangiocarcinoma in the United States pre- and post-the advent of gemcitabine/cisplatin
Journal of Gastrointestinal Oncology, 2018, 9, 1063-1073
0.914Citations (PDF)
159Tu1497 - Determinants of Patients Outcomes Following Locoregional Ablation of Hepatocellular Carcinoma
Gastroenterology, 2018, 154, S-1239
0.90Citations (PDF)
160Hypothyroidism is associated with worse outcomes of hepatocellular carcinoma patients after liver transplantation
Cancer Medicine, 2018, 7, 5870-5878
2.016Citations (PDF)
161Management of Combined Hepatocellular Carcinoma-Cholangiocarcinoma
Current Hepatology Reports, 2018, 17, 385-391
0.94Citations (PDF)
162A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily
Cell Systems, 2018, 7, 422-437.e7
3.7177Citations (PDF)
163A model predicting short-term mortality in patients with advanced liver cirrhosis and concomitant infection
Medicine (United States), 2018, 97, e12758
1.010Citations (PDF)
164Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer
Cell Reports, 2018, 25, 1304-1317.e5
4.4507Citations (PDF)
165Gastrointestinal and Extra-Intestinal Manifestations of IgG4–Related Disease
Gastroenterology, 2018, 155, 990-1003.e1
0.980Citations (PDF)
1661042 - Aspirin, Other Nsaids and Statins Reduce the Risk of Biliary Tract Cancers: A Swedish Nationwide Population-Based Cohort Study
Gastroenterology, 2018, 154, S-1113
0.91Citations (PDF)
167Su1459 - Aurora Kinase a Sustains Cholangiocarcinoma Proliferation and Represents a New Therapeutic Target
Gastroenterology, 2018, 154, S-1153
0.90Citations (PDF)
168Sa1480 - Understanding the Immunological Profiles of Somaliamericans with Viral Hepatitis
Gastroenterology, 2018, 154, S-1126-S-1127
0.90Citations (PDF)
169Sa1491 - Chronic HBV Infected Patients in Burkina Faso have Low HBV Viral Load Compared to Patients from Taiwan
Gastroenterology, 2018, 154, S-1130-S-1131
0.90Citations (PDF)
170Su1457 - Targeting Sphingosine Kinase 2 Suppresses Cell Proliferation Through Noxa-Mediated MCL-1 Degradation in Cholangiocarcinoma and Synergizes with BH3-Mimetics
Gastroenterology, 2018, 154, S-1153
0.90Citations (PDF)
171Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients
Cancer Cell, 2018, 34, 211-224.e6
28.7915Citations (PDF)
172Non-alcoholic fatty liver disease-associated hepatocellular carcinoma: effect of hepatic steatosis on major hepatocellular carcinoma features at MRI
British Journal of Radiology, 2018, 91,
1.929Citations (PDF)
173Prevalent hepatitis B surface antigen among first-time blood donors in Gabon
PLoS ONE, 2018, 13, e0194285
1.528Citations (PDF)
174Heat Stress and Hepatic Laser Thermal Ablation Induce Hepatocellular Carcinoma Growth: Role of PI3K/mTOR/AKT Signaling
Radiology, 2018, 288, 730-738
7.035Citations (PDF)
175DNA Methylation of Telomere-Related Genes and Cancer Risk
Cancer Prevention Research, 2018, 11, 511-522
1.218Citations (PDF)
176Initiation of aberrant DNA methylation patterns and heterogeneity in precancerous lesions of human hepatocellular cancer
Epigenetics, 2017, 12, 215-225
2.136Citations (PDF)
177Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium
The Lancet Gastroenterology and Hepatology, 2017, 2, 103-111
14.9244Citations (PDF)
178Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
The Lancet Gastroenterology and Hepatology, 2017, 2, 161-176
14.91,813Citations (PDF)
179Improved Performance of Serum Alpha-Fetoprotein for Hepatocellular Carcinoma Diagnosis in HCV Cirrhosis with Normal Alanine Transaminase
Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1085-1092
0.659Citations (PDF)
180Inhibiting histone deacetylases suppresses glucose metabolism and hepatocellular carcinoma growth by restoring FBP1 expression
Scientific Reports, 2017, 7,
2.789Citations (PDF)
181Should AFP (or Any Biomarkers) Be Used for HCC Surveillance?
Current Hepatology Reports, 2017, 16, 137-145
0.938Citations (PDF)
182Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Cell, 2017, 169, 1327-1341.e23
23.82,319Citations (PDF)
183Recent Trends in the Epidemiology of Hepatocellular Carcinoma in Olmsted County, Minnesota
Journal of Clinical Gastroenterology, 2017, 51, 742-748
1.338Citations (PDF)
184Identification of fucosylated Fetuin‐A as a potential biomarker for cholangiocarcinoma
Proteomics - Clinical Applications, 2017, 11,
1.523Citations (PDF)
185Early Age Hepatocellular Carcinoma Associated With Hepatitis B Infection in South America
Clinical Gastroenterology and Hepatology, 2017, 15, 1631-1632
5.326Citations (PDF)
186Characteristics of US-Born Versus Foreign-Born Americans of African Descent With Chronic Hepatitis B
American Journal of Epidemiology, 2017, 186, 356-366
2.416Citations (PDF)
187Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
Cell Reports, 2017, 18, 2780-2794
4.4524Citations (PDF)
188Microsurgical reconstruction in patients greater than 80 years old
Microsurgery, 2017, 37, 546-551
0.830Citations (PDF)
189Hepatocellular Carcinoma Is the Most Common Indication for Liver Transplantation and Placement on the Waitlist in the United States
Clinical Gastroenterology and Hepatology, 2017, 15, 767-775.e3
5.3141Citations (PDF)
190MR elastography of hepatocellular carcinoma: Correlation of tumor stiffness with histopathology features—Preliminary findings
Magnetic Resonance Imaging, 2017, 37, 41-45
1.275Citations (PDF)
191Clinical, Biochemical, and Histopathology Features of Patients With Glycogenic Hepatopathy
Clinical Gastroenterology and Hepatology, 2017, 15, 927-933
5.334Citations (PDF)
192To reverse or not to reverse? A systematic review of autograft polarity on functional outcomes following peripheral nerve repair surgery
Microsurgery, 2017, 37, 169-174
0.832Citations (PDF)
193Comprehensive assessment of circulating immune cell populations in response to stereotactic body radiation therapy in patients with liver cancer
Advances in Radiation Oncology, 2017, 2, 540-547
1.131Citations (PDF)
194Sleeping Beauty Insertional Mutagenesis in Mice Identifies Drivers of Steatosis-Associated Hepatic Tumors
Cancer Research, 2017, 77, 6576-6588
4.244Citations (PDF)
195Increased Prevalence of Metabolic Risk Factors in Asian Americans With Hepatocellular Carcinoma
Journal of Clinical Gastroenterology, 2017, 51, 384-390
1.38Citations (PDF)
196Racial and Socioeconomic Disparities in the Incidence Rates and Survival of Gallbladder Cancer in the United States
Gastroenterology, 2017, 152, S1172-S1173
0.94Citations (PDF)
197Male Sex is a Risk Factor for Poorer Long-Term Overall Survival for White Patients with Hepatocellular Carcinoma (HCC) but not for Black Patients with HCC
Gastroenterology, 2017, 152, S1177-S1178
0.90Citations (PDF)
198Black Patients with Hepatocellular Carcinoma (HCC) Diagnosed After 2010 have Worse Long-Term Survival Than White Patients
Gastroenterology, 2017, 152, S1173-S1174
0.91Citations (PDF)
199Race Specific Trends in Incidence Rates of Hepatocellular Carcinoma in the United States
Gastroenterology, 2017, 152, S1174
0.90Citations (PDF)
200Effect of Coffee Consumption on Cholangiocarcinoma Risk and Survival
Gastroenterology, 2017, 152, S1176
0.90Citations (PDF)
201High fat diet and exercise lead to a disrupted and pathogenic DNA methylome in mouse liver
Epigenetics, 2017, 12, 55-69
2.150Citations (PDF)
202Novel Deleterious Dihydropyrimidine Dehydrogenase Variants May Contribute to 5‐Fluorouracil Sensitivity in an East African Population
Clinical Pharmacology and Therapeutics, 2017, 101, 382-390
2.742Citations (PDF)
203Impact of country of birth on age at the time of diagnosis of hepatocellular carcinoma in the United States
Cancer, 2017, 123, 81-89
2.765Citations (PDF)
204Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list
Hepatology, 2017, 65, 777-788
9.588Citations (PDF)
205Transcriptional Induction of Periostin by a Sulfatase 2–TGFβ1–SMAD Signaling Axis Mediates Tumor Angiogenesis in Hepatocellular Carcinoma
Cancer Research, 2017, 77, 632-645
4.267Citations (PDF)
206Decreased Expression of Sulfatase 2 in the Brains of Alzheimer’s Disease Patients: Implications for Regulation of Neuronal Cell Signaling
Journal of Alzheimer's Disease Reports, 2017, 1, 115-124
1.620Citations (PDF)
207Venous invasion by hepatic tumors: imaging appearance and implications for management
Abdominal Radiology, 2017, 43, 1947-1967
1.217Citations (PDF)
208Molecular testing for the clinical diagnosis of fibrolamellar carcinoma
Modern Pathology, 2017, 31, 141-149
3.867Citations (PDF)
209Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances
F1000Research, 2016, 5, 879
0.3189Citations (PDF)
210Heat Stress-Induced PI3K/mTORC2-Dependent AKT Signaling Is a Central Mediator of Hepatocellular Carcinoma Survival to Thermal Ablation Induced Heat Stress
PLoS ONE, 2016, 11, e0162634
1.527Citations (PDF)
211Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma
Journal of Hepatology, 2016, 65, 859-860
7.4128Citations (PDF)
212Aspirin use and the risk of cholangiocarcinoma‡
Hepatology, 2016, 64, 785-796
9.5100Citations (PDF)
213Statins and metformin for chemoprevention of hepatocellular carcinoma
Clinical Liver Disease, 2016, 8, 48-52
0.517Citations (PDF)
21411 The Casein Kinase II Inhibitor CX-4945 Has an Additive Effect With Gemcitabine and Cisplatin on Cholangiocarcinoma Xenografts
Gastroenterology, 2016, 150, S4
0.90Citations (PDF)
215Mo1495 Hepatocellular Carcinoma in South America: Predominance of Hepatitis C Etiology and Late Diagnosis
Gastroenterology, 2016, 150, S1130
0.90Citations (PDF)
216Fluorescence in situ hybridization compared with conventional cytology for the diagnosis of malignant biliary tract strictures in Asian patients
Gastrointestinal Endoscopy, 2016, 83, 1228-1235
1.438Citations (PDF)
217Sa1128 Hepatocellular Carcinoma Characteristics and Outcomes among Somali Immigrants vs. Non-Hispanic Whites
Gastroenterology, 2016, 150, S249-S250
0.91Citations (PDF)
218651 Impact of Country of Birth on the Age of Onset of Hepatocellular Carcinoma in the United States
Gastroenterology, 2016, 150, S1042-S1043
0.90Citations (PDF)
21913 Differential Characteristics of Black and White Patients With Hepatocellular Carcinoma (HCC)
Gastroenterology, 2016, 150, S4-S5
0.90Citations (PDF)
220Sa1607 Clinical, Biochemical and Histopathological Profile of Subjects With Glycogenic Hepatopathy and Comparison With Type 1 Diabetes Patients
Gastroenterology, 2016, 150, S340-S341
0.90Citations (PDF)
221Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein
Cancer Letters, 2016, 380, 163-173
6.785Citations (PDF)
222Sa1362 Identification of Novel Fusions in Gallbladder Cancer by Next Generation Sequencing RNA Analysis - Potential for Targeted Therapy
Gastroenterology, 2016, 150, S295-S296
0.90Citations (PDF)
223Circulating tumor cells are associated with poor overall survival in patients with cholangiocarcinoma
Hepatology, 2016, 63, 148-158
9.588Citations (PDF)
224Implications of CA19-9 elevation for survival, staging, and treatment sequencing in intrahepatic cholangiocarcinoma: A national cohort analysis
Journal of Surgical Oncology, 2016, 114, 475-482
1.272Citations (PDF)
225p62/SQSTM1 by Binding to Vitamin D Receptor Inhibits Hepatic Stellate Cell Activity, Fibrosis, and Liver Cancer
Cancer Cell, 2016, 30, 595-609
28.7226Citations (PDF)
226Diabetes Mellitus Heightens the Risk of Hepatocellular Carcinoma Except in Patients With Hepatitis C Cirrhosis
American Journal of Gastroenterology, 2016, 111, 1573-1580
0.668Citations (PDF)
227Silent Tyrosinemia Type I Without Elevated Tyrosine or Succinylacetone Associated with Liver Cirrhosis and Hepatocellular Carcinoma
Human Mutation, 2016, 37, 1097-1105
1.032Citations (PDF)
228Anti-invasion and anti-migration effects of miR-199a-3p in hepatocellular carcinoma are due in part to targeting CD151
International Journal of Oncology, 2016, 49, 2037-2045
3.733Citations (PDF)
229426 Disagreement Between the World Congress of Gastroenterology Guidelines and the American Society of Echocardiography Guidelines for the Diagnosis of Diastolic Dysfunction Among Patients With Advanced Liver Diseas
Gastroenterology, 2016, 150, S1033-S1034
0.90Citations (PDF)
230Mo1498 Non-Alcoholic Fatty Liver Disease (NAFLD) and Hepatocellular Carcinoma (HCC) in Maritime South East Asians (MSEAS)
Gastroenterology, 2016, 150, S1131-S1132
0.90Citations (PDF)
231Mo1509 The Presence of Cirrhosis Does Not Worsen the Survival of Patients With Cholangiocarcinoma
Gastroenterology, 2016, 150, S1135
0.90Citations (PDF)
232Mo1510 Prognosis of Patients With Hepatocellular Carcinoma Is Extremely Poor in African Country
Gastroenterology, 2016, 150, S1135-S1136
0.90Citations (PDF)
233Mo1515 Recent Trends in HCC Epidemiology in Olmsted County, Minnesota
Gastroenterology, 2016, 150, S1137
0.90Citations (PDF)
234Sa1618 Patterns of Left Ventricular Hypertrophy and Adverse Outcomes in Liver Transplant Recipients Without a History of Hypertension
Gastroenterology, 2016, 150, S1077-S1078
0.90Citations (PDF)
235Mo1479 Serum Alpha Fetoprotein in Hepatocellular Carcinoma: Effect of Etiology, Race, and Severity of Liver Inflammation
Gastroenterology, 2016, 150, S1126
0.90Citations (PDF)
236647 Validation of the GALAD Score for Prediction of Hepatocellular Carcinoma at a US Tertiary Referral Center and Comparison of its Performance to Liver Ultrasound
Gastroenterology, 2016, 150, S1041
0.92Citations (PDF)
237A new HIF‐1α/RANTES‐driven pathway to hepatocellular carcinoma mediated by germline haploinsufficiency of SART1/HAF in mice
Hepatology, 2016, 63, 1576-1591
9.544Citations (PDF)
238Hepatitis B Virus–Specific and Global T-Cell Dysfunction in Chronic Hepatitis B
Gastroenterology, 2016, 150, 684-695.e5
0.9221Citations (PDF)
239Clinical implications of basic research in hepatocellular carcinoma
Journal of Hepatology, 2016, 64, 736-745
7.449Citations (PDF)
240Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance)
Targeted Oncology, 2016, 12, 201-209
2.529Citations (PDF)
241Mo1024 Allelic Distribution of SNPs Relevant to Hepatitis B and C Viral Infection Among Minnesota's Somali Population
Gastroenterology, 2015, 148, S-1066
0.90Citations (PDF)
242Vasodilator‐stimulated phosphoprotein promotes activation of hepatic stellate cells by regulating Rab11‐dependent plasma membrane targeting of transforming growth factor beta receptors
Hepatology, 2015, 61, 361-374
9.572Citations (PDF)
243Association between variants in inflammation and cancer‐associated genes and risk and survival of cholangiocarcinoma
Cancer Medicine, 2015, 4, 1599-1602
2.012Citations (PDF)
244Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study
Liver International, 2015, 35, 2155-2166
3.11,182Citations (PDF)
245Elevated free fatty acid uptake via CD36 promotes epithelial-mesenchymal transition in hepatocellular carcinoma
Scientific Reports, 2015, 5,
2.7322Citations (PDF)
246Integration of extracellular RNA profiling data using metadata, biomedical ontologies and Linked Data technologies
Journal of Extracellular Vesicles, 2015, 4,
11.154Citations (PDF)
247Mo1045 A Nationwide Demographic and Socioeconomic Analysis of Endoscopic Biliary Stent Utilization in Patients With Cholangiocarcinoma
Gastroenterology, 2015, 148, S-1072
0.90Citations (PDF)
248Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation
Liver Transplantation, 2015, 21, 599-606
1.6118Citations (PDF)
249Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma
Current Opinion in Gastroenterology, 2015, 31, 264-268
1.654Citations (PDF)
250Unique Genomic Profile of Fibrolamellar Hepatocellular Carcinoma
Gastroenterology, 2015, 148, 806-818.e10
0.9123Citations (PDF)
251DNAJB1-PRKACA is specific for fibrolamellar carcinoma
Modern Pathology, 2015, 28, 822-829
3.8174Citations (PDF)
252Screening for Hepatocellular Carcinoma and Cholangiocarcinoma: Can Biomarkers Replace Imaging?
Current Hepatology Reports, 2015, 14, 128-138
0.910Citations (PDF)
253Classification and Staging of Hepatocellular Carcinoma
Clinics in Liver Disease, 2015, 19, 277-294
1.625Citations (PDF)
254587 The Model for End-Stage Liver Disease Score Stratifies Elderly Cirrhotic Patients Admitted to the Intensive Care Unit Who Had Comparable Outcomes to the Young Patients
Gastroenterology, 2015, 148, S-987
0.90Citations (PDF)
255Sa1858 Undiagnosed Nonalcoholic Steatohepatitis (NASH) Is Responsible for a Significant Proportion of Cryptogenic Hepatocellular Carcinoma (HCC)
Gastroenterology, 2015, 148, S-1026
0.90Citations (PDF)
256Sa1868 Metformin Use Reduces Intrahepatic Cholangiocarcinoma Risk in Patients With Diabetes but Does Not Improve Survival of Cholangiocarcinoma
Gastroenterology, 2015, 148, S-1029-S-1030
0.91Citations (PDF)
257Sa1864 Factors Influencing Surveillance for Hepatocellular Carcinoma in Patients With Liver Cirrhosis
Gastroenterology, 2015, 148, S-1027-S-1028
0.90Citations (PDF)
258583 A New Clinically Based Staging System for Intrahepatic Cholangiocarcinoma
Gastroenterology, 2015, 148, S-986
0.90Citations (PDF)
259Sa1716 Next Generation Sequencing and Pathway Analysis Reveals Frequent Activation of the PI3-K/Akt Pathway in Gallbladder Cancer: Potential for Targeted Therapy
Gastroenterology, 2015, 148, S-1019
0.90Citations (PDF)
260Biphenotypic hepatic tumors: imaging findings and review of literature
Abdominal Imaging, 2015, 40, 2293-2305
1.953Citations (PDF)
261An Optimized Set of Fluorescence In Situ Hybridization Probes for Detection of Pancreatobiliary Tract Cancer in Cytology Brush Samples
Gastroenterology, 2015, 149, 1813-1824.e1
0.9146Citations (PDF)
262The role of hepatic resection in the treatment of hepatocellular cancer
Hepatology, 2015, 62, 440-451
9.5388Citations (PDF)
263Histone acetyltransferase PCAF accelerates apoptosis by repressing a GLI1/BCL2/BAX axis in hepatocellular carcinoma
Cell Death and Disease, 2015, 6, e1712-e1712
6.650Citations (PDF)
264Hepatocellular Carcinoma Occurs at an Earlier Age in Africans, Particularly in Association With Chronic Hepatitis B
American Journal of Gastroenterology, 2015, 110, 1629-1631
0.690Citations (PDF)
265Prognostic Value of Model for End-Stage Liver Disease Score Measurements on a Daily Basis in Critically Ill Patients With Cirrhosis
Mayo Clinic Proceedings, 2015, 90, 1196-1206
2.06Citations (PDF)
266Characteristics of Adults in the Hepatitis B Research Network in North America Reflect Their Country of Origin and Hepatitis B Virus Genotype
Clinical Gastroenterology and Hepatology, 2015, 13, 183-192
5.398Citations (PDF)
267Activation of the transforming growth factor‐β/SMAD transcriptional pathway underlies a novel tumor‐promoting role of sulfatase 1 in hepatocellular carcinoma
Hepatology, 2015, 61, 1269-1283
9.560Citations (PDF)
268Update on Biomarkers of Hepatocellular Carcinoma
Clinical Gastroenterology and Hepatology, 2015, 13, 237-245
5.3131Citations (PDF)
269Long and Short Telomere Lengths are Associated with Risk of Amnestic Mild Cognitive Impairment (S33.002)
Neurology, 2015, 84,
0.70Citations (PDF)
270Brivanib Attenuates Hepatic Fibrosis In Vivo and Stellate Cell Activation In Vitro by Inhibition of FGF, VEGF and PDGF Signaling
PLoS ONE, 2014, 9, e92273
1.552Citations (PDF)
271639 Female Gender Associated With Less Aggressive Tumor Phenotype and Better Survival in HCC
Gastroenterology, 2014, 146, S-918
0.90Citations (PDF)
272Role for Putative Hepatocellular Carcinoma Stem Cell Subpopulations in Biological Response to Incomplete Thermal Ablation: In Vitro and In Vivo Pilot Study
CardioVascular and Interventional Radiology, 2014, 37, 1343-1351
1.217Citations (PDF)
273Fibroblast growth factor signaling in liver carcinogenesis
Hepatology, 2014, 59, 1166-1173
9.577Citations (PDF)
274Liver Masses: A Clinical, Radiologic, and Pathologic Perspective
Clinical Gastroenterology and Hepatology, 2014, 12, 1414-1429
5.3101Citations (PDF)
275A New Clinically Based Staging System for Perihilar Cholangiocarcinoma
American Journal of Gastroenterology, 2014, 109, 1881-1890
0.691Citations (PDF)
276Short and long telomeres increase risk of amnestic mild cognitive impairment
Mechanisms of Ageing and Development, 2014, 141-142, 64-69
3.943Citations (PDF)
277Platelet-derived Growth Factor Primes Cancer-associated Fibroblasts for Apoptosis
Journal of Biological Chemistry, 2014, 289, 22835-22849
1.353Citations (PDF)
278Treating Hepatitis C in Lower-Income Countries
New England Journal of Medicine, 2014, 370, 1869-1871
19.476Citations (PDF)
279Sa1703 High Levels of Non-Clonal Serum Immunoglobulin Free Light Chains As a Biomarker of Hepatobiliary Disorders
Gastroenterology, 2014, 146, S-955
0.90Citations (PDF)
280Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma
Human Pathology, 2014, 45, 1630-1638
1.7296Citations (PDF)
281Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes
Hepatology, 2014, 60, 2008-2016
9.5169Citations (PDF)
282Rethinking cancer immunotherapy: Using advanced cancer genetics in immune‐mediated eradication of gastrointestinal cancers
Hepatology, 2014, 60, 2121-2124
9.54Citations (PDF)
283Su1000 Enhanced Liver Tumorigenesis in Sulfatase 1 (SULF1) Transgenic Mice Is Associated With Activation of the Wnt-β-Catenin Signaling Pathway
Gastroenterology, 2013, 144, S-991
0.90Citations (PDF)
284631 Circulating Tumor Cells Are Associated With More Advanced Disease in Cholangiocarcinoma
Gastroenterology, 2013, 144, S-957
0.91Citations (PDF)
285Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas
Nature Genetics, 2013, 45, 1470-1473
14.1638Citations (PDF)
286Therapeutic Effects of Deleting Cancer-Associated Fibroblasts in Cholangiocarcinoma
Cancer Research, 2013, 73, 897-907
4.2193Citations (PDF)
287The human sulfatase 2 inhibitor 2,4‐disulfonylphenyl‐tert‐butylnitrone (OKN‐007) has an antitumor effect in hepatocellular carcinoma mediated via suppression of TGFB1/SMAD2 and Hedgehog/GLI1 signaling
Genes Chromosomes and Cancer, 2013, 52, 225-236
1.664Citations (PDF)
288Genetic alterations in advanced HBV-related HCC with portal vein tumor thrombosis: Insights from next generation DNA sequencing
Journal of Hepatology, 2013, 58, 1042-1044
7.45Citations (PDF)
289Tu1039 Is NASH Related HCC Different From HCC Related to Other Causes
Gastroenterology, 2013, 144, S-1038
0.90Citations (PDF)
290629 A New Staging System for Perihilar Cholangiocarcinoma
Gastroenterology, 2013, 144, S-956
0.90Citations (PDF)
291Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions
Human Pathology, 2013, 44, 1216-1222
1.7137Citations (PDF)
292Risk Factors for Intrahepatic Cholangiocarcinoma: Association Between Metformin Use and Reduced Cancer Risk
Hepatology, 2013, 57, 648-655
9.5133Citations (PDF)
293Identification of Rtl1, a Retrotransposon-Derived Imprinted Gene, as a Novel Driver of Hepatocarcinogenesis
PLoS Genetics, 2013, 9, e1003441
2.282Citations (PDF)
294Primary sclerosing cholangitis with equivocal cytology: Fluorescence in situ hybridization and serum CA 19‐9 predict risk of malignancy
Cancer Cytopathology, 2013, 121, 708-717
1.375Citations (PDF)
295Activation of the Transcription Factor GLI1 by WNT Signaling Underlies the Role of SULFATASE 2 as a Regulator of Tissue Regeneration
Journal of Biological Chemistry, 2013, 288, 21389-21398
1.336Citations (PDF)
296Molecular Bioluminescence Imaging as a Noninvasive Tool for Monitoring Tumor Growth and Therapeutic Response to MRI-Guided Laser Ablation in a Rat Model of Hepatocellular Carcinoma
Investigative Radiology, 2013, 48, 413-421
4.322Citations (PDF)
297Chemopreventive strategies in hepatocellular carcinoma
Nature Reviews Gastroenterology and Hepatology, 2013, 11, 45-54
31.1255Citations (PDF)
298Methylated Bone Morphogenetic Protein 3 (BMP3) Gene: Evaluation of Tumor Suppressor Function and Biomarker Potential in Biliary Cancer
Journal of Molecular Biomarkers & Diagnosis, 2013, 04,
0.015Citations (PDF)
299Hepatic Artery Embolization for Neuroendocrine Tumors: Postprocedural Management and Complications
Oncologist, 2012, 17, 725-731
2.437Citations (PDF)
300Biliary Tract Cancers in Olmsted County, Minnesota, 1976–2008
American Journal of Gastroenterology, 2012, 107, 1256-1262
0.677Citations (PDF)
301Metallothionein MT1M is a tumor suppressor of human hepatocellular carcinomas
Carcinogenesis, 2012, 33, 2568-2577
2.280Citations (PDF)
302Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutic Targets for Tyrosine Kinase Inhibitors
Gastroenterology, 2012, 142, 1021-1031.e15
0.9531Citations (PDF)
303Silencing of HSulf-2 expression in MCF10DCIS.com cells attenuate ductal carcinoma in situ progression to invasive ductal carcinoma in vivo
Breast Cancer Research, 2012, 14,
3.416Citations (PDF)
304New issues in the pathogenesis of hepatocellular carcinoma: Applying insights from next-generation DNA sequencing technologies to improve therapy for hepatocellular carcinoma
Clinical Liver Disease, 2012, 1, 200-205
0.51Citations (PDF)
305Viral Hepatitis Among Somali Immigrants in Minnesota: Association of Hepatitis C With Hepatocellular Carcinoma
Mayo Clinic Proceedings, 2012, 87, 17-24
2.040Citations (PDF)
306Hepatocellular Carcinoma in Olmsted County, Minnesota, 1976-2008
Mayo Clinic Proceedings, 2012, 87, 9-16
2.041Citations (PDF)
307696 Lack of Association Between NKG2D Polymorphisms and Cholangiocarcinoma (CCA) Risk in Primary Sclerosing Cholangitis (PSC) and Non-PSC Patients
Gastroenterology, 2012, 142, S-922
0.91Citations (PDF)
308Development and Preliminary Testing of a Translational Model of Hepatocellular Carcinoma for MR Imaging and Interventional Oncologic Investigations
Journal of Vascular and Interventional Radiology, 2012, 23, 385-395
1.124Citations (PDF)
309Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo
Journal of Hepatology, 2012, 56, 176-183
7.442Citations (PDF)
310Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma
Journal of Hepatology, 2012, 56, 486-487
7.49Citations (PDF)
311Comparison of Methods to Detect Neoplasia in Patients Undergoing Endoscopic Ultrasound-Guided Fine-Needle Aspiration
Gastroenterology, 2012, 142, 1112-1121.e2
0.943Citations (PDF)
312Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma
Human Pathology, 2012, 43, 1552-1558
1.7240Citations (PDF)
313Su2056 Associations Between Etiology, Tumor Extent, and Alpha Fetoprotein in Patients With Hepatocellular Carcinoma
Gastroenterology, 2012, 142, S-984
0.90Citations (PDF)
314Model to estimate survival in ambulatory patients with hepatocellular carcinoma
Hepatology, 2012, 56, 614-621
9.596Citations (PDF)
315AS30D Model of Hepatocellular Carcinoma: Tumorigenicity and Preliminary Characterization by Imaging, Histopathology, and Immunohistochemistry
CardioVascular and Interventional Radiology, 2012, 36, 198-203
1.214Citations (PDF)
316Efficacy and Safety of Transarterial Radioembolization Versus Chemoembolization in Patients With Hepatocellular Carcinoma
CardioVascular and Interventional Radiology, 2012, 36, 714-723
1.2136Citations (PDF)
317Silencing of miR-370 in Human Cholangiocarcinoma by Allelic Loss and Interleukin-6 Induced Maternal to Paternal Epigenotype Switch
PLoS ONE, 2012, 7, e45606
1.548Citations (PDF)
318The Transcription Factor GLI1 Mediates TGFβ1 Driven EMT in Hepatocellular Carcinoma via a SNAI1-Dependent Mechanism
PLoS ONE, 2012, 7, e49581
1.572Citations (PDF)
319Factors That Affect Risk for Hepatocellular Carcinoma and Effects of Surveillance
Clinical Gastroenterology and Hepatology, 2011, 9, 617-623.e1
5.3121Citations (PDF)
320Cirrhosis Is Present in Most Patients With Hepatitis B and Hepatocellular Carcinoma
Clinical Gastroenterology and Hepatology, 2011, 9, 64-70
5.3240Citations (PDF)
321Circulating Tumor Cells in Cholangiocarcinoma
Gastroenterology, 2011, 140, S-921
0.90Citations (PDF)
322Knockout of Sulfatase 2 (SULF2) Decreases Liver Fibrosis
Gastroenterology, 2011, 140, S-979
0.90Citations (PDF)
323Transarterial Radioembolization in Advanced Stage Hepatocellular Carcinoma
Gastroenterology, 2011, 140, S-913
0.90Citations (PDF)
324Decreased Liver Tumorigenesis in Sulfatase 2 (SULF2) Knockout Mice May Be Mediated Through Inhibition of the Epithelial-Mesenchymal Transition (EMT)
Gastroenterology, 2011, 140, S-680
0.90Citations (PDF)
325Comparison of Transarterial Radioembolization (Tare) and Transarterial Chemoembolization (TACE) for the Treatment of Unresectable Intrahepatic Cholangiocarcinoma
Gastroenterology, 2011, 140, S-920-S-921
0.93Citations (PDF)
326Obesity is Not a Risk Factor for Hepatocellular Carcinoma in Patients With Cirrhosis
Gastroenterology, 2011, 140, S-921
0.90Citations (PDF)
327The tumor microenvironment in hepatocellular carcinoma: Current status and therapeutic targets
Seminars in Cancer Biology, 2011, 21, 35-43
10.7362Citations (PDF)
328Utility of serum immunoglobulin G4 in distinguishing immunoglobulin G4-associated cholangitis from cholangiocarcinoma
Hepatology, 2011, 54, 940-948
9.5189Citations (PDF)
329Sulfatase 1 and sulfatase 2 in hepatocellular carcinoma: Associated signaling pathways, tumor phenotypes, and survival
Genes Chromosomes and Cancer, 2011, 50, 122-135
1.660Citations (PDF)
330Hedgehog Inhibition Promotes a Switch from Type II to Type I Cell Death Receptor Signaling in Cancer Cells
PLoS ONE, 2011, 6, e18330
1.530Citations (PDF)
331The Oncogenic Effect of Sulfatase 2 in Human Hepatocellular Carcinoma Is Mediated in Part by Glypican 3–Dependent Wnt Activation
Hepatology, 2010, 52, 1680-1689
9.5110Citations (PDF)
332Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors
Liver International, 2010, 30, 1522-1528
3.130Citations (PDF)
333GLI3-dependent repression of DR4 mediates hedgehog antagonism of TRAIL-induced apoptosis
Oncogene, 2010, 29, 4848-4858
5.247Citations (PDF)
334S1887 Knockout of Sulfatase 2 (SULF2) Decreases Liver Regeneration After Partial Hepatectomy
Gastroenterology, 2010, 138, S-810
0.90Citations (PDF)
335S1902 Liver Fibrosis in Patients With Hepatocellular Carcinoma: Comparison Between Hepatitis B and C
Gastroenterology, 2010, 138, S-813
0.90Citations (PDF)
336843 SULF1 and SULF2 Correlated Genes in Hepatocellular Carcinoma (HCC) as Revealed by Genome-Wide Gene Expression Microarray Analysis
Gastroenterology, 2010, 138, S-797
0.90Citations (PDF)
337S1886 Hepatitis C Virus is a Major Risk Factor for Hepatocellular Carcinoma in Somalis
Gastroenterology, 2010, 138, S-810
0.90Citations (PDF)
338Comparison of KRAS Mutation Analysis and FISH for Detecting Pancreatobiliary Tract Cancer in Cytology Specimens Collected During Endoscopic Retrograde Cholangiopancreatography
Journal of Molecular Diagnostics, 2010, 12, 780-786
2.174Citations (PDF)
339Hepatocellular carcinoma: a global view
Nature Reviews Gastroenterology and Hepatology, 2010, 7, 448-458
31.11,236Citations (PDF)
340miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines
Biochemical and Biophysical Research Communications, 2010, 403, 120-125
1.5136Citations (PDF)
34177 Predictors of Mortality in Perihilar Cholangiocarcinoma
Gastroenterology, 2010, 138, S-775
0.90Citations (PDF)
342Epidemiology and Management of Hepatocellular Carcinoma
Infectious Disease Clinics of North America, 2010, 24, 899-919
1.7182Citations (PDF)
343Rare Distant Skeletal Muscle Metastasis from Hilar Cholangiocarcinoma: Report of a Case
Journal of Gastrointestinal Cancer, 2010, 42, 171-173
1.17Citations (PDF)
344Utility of Serum YKL-40 as a Tumor-Specific Marker of Hepatobiliary Malignancies
Gut and Liver, 2010, 4, 537-542
1.75Citations (PDF)
345The Tumor Suppressor Function of Human Sulfatase 1 (SULF1) in Carcinogenesis
Journal of Gastrointestinal Cancer, 2009, 39, 149-158
1.193Citations (PDF)
346Liver transplantation after radioembolization in a patient with unresectable HCC
Nature Reviews Gastroenterology and Hepatology, 2009, 6, 679-683
31.113Citations (PDF)
347Additive effect of apicidin and doxorubicin in sulfatase 1 expressing hepatocellular carcinoma in vitro and in vivo
Journal of Hepatology, 2009, 50, 1112-1121
7.435Citations (PDF)
348A Multivariable Model Using Advanced Cytologic Methods for the Evaluation of Indeterminate Pancreatobiliary Strictures
Gastroenterology, 2009, 136, 2180-2186
0.9190Citations (PDF)
349α-Fetoprotein, Des-γ Carboxyprothrombin, and Lectin-Bound α-Fetoprotein in Early Hepatocellular Carcinoma
Gastroenterology, 2009, 137, 110-118
0.9750Citations (PDF)
350A new, effective and high-yield approach for identifying liver tumor suppressors
Genome Medicine, 2009, 1, 26
5.91Citations (PDF)
351168 SULF2 Promotes Tumorigenesis of Hepatocellular Carcinoma By Activating the Wnt/β-Catenin Pathway
Gastroenterology, 2009, 136, A-793
0.90Citations (PDF)
352Hepatic Vein Tumor Thrombus as a Risk Factor for Excessive Pulmonary Deposition of Microspheres during TheraSphere Therapy for Unresectable Hepatocellular Carcinoma
Journal of Vascular and Interventional Radiology, 2009, 20, 1460-1463
1.122Citations (PDF)
353W1007 Mean Liver Stiffness Value Is Not Associated with Risk of Hepatocellular Carcinoma in Patients with Compensated Cirrhosis: Preliminary Results
Gastroenterology, 2009, 136, A-857
0.90Citations (PDF)
354M2067 The Utility of Serum IgG4 Levels in Distinguishing Cholangiocarcinoma (CCA) from IgG4-Associated Cholangitis (IAC)
Gastroenterology, 2009, 136, A-478
0.90Citations (PDF)
355Epigenetic DNA hypermethylation in cholangiocarcinoma: potential roles in pathogenesis, diagnosis and identification of treatment targets
Liver International, 2008, 28, 12-27
3.152Citations (PDF)
356Diagnosis and management of cholangiocarcinoma
Current Gastroenterology Reports, 2008, 10, 43-52
2.231Citations (PDF)
357Sulfatase 2 up‐regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma†
Hepatology, 2008, 47, 1211-1222
9.5200Citations (PDF)
358574 Down-Regulation of Sulf1 By Hypermethylation Mediates Resistance of Hepatocellular Carcinoma Cells to Chemotherapy-Induced Apoptosis
Gastroenterology, 2008, 134, A-767-A-768
0.90Citations (PDF)
359The JNK inhibitor SP600129 enhances apoptosis of HCC cells induced by the tumor suppressor WWOX
Journal of Hepatology, 2008, 49, 373-383
7.445Citations (PDF)
360279 Sulf2 Up-Regulates Glypican 3, Promotes FGF Signaling, and Decreases Survival of Patients with Hepatocellular Carcinoma (HCC)
Gastroenterology, 2008, 134, A-762
0.90Citations (PDF)
361Clinical Challenges and Images in GI
Gastroenterology, 2008, 135, 18-328
0.91Citations (PDF)
362Treatment options for hepatocellular carcinoma
Expert Review of Gastroenterology and Hepatology, 2008, 2, 81-92
1.731Citations (PDF)
363Heparin-Degrading Sulfatases in Hepatocellular Carcinoma: Roles in Pathogenesis and Therapy Targets
Future Oncology, 2008, 4, 803-814
1.756Citations (PDF)
364Correlating Routine Cytology, Quantitative Nuclear Morphometry by Digital Image Analysis, and Genetic Alterations by Fluorescence In Situ Hybridization to Assess the Sensitivity of Cytology for Detecting Pancreatobiliary Tract Malignancy
American Journal of Clinical Pathology, 2007, 128, 272-279
0.474Citations (PDF)
365An assessment of chromosomal alterations detected by fluorescence in situ hybridization and p16 expression in sporadic and primary sclerosing cholangitis-associated cholangiocarcinomas
Human Pathology, 2007, 38, 491-499
1.756Citations (PDF)
366Hypothyroidism: A Possible Risk Factor for Liver Cancer in Patients With No Known Underlying Cause of Liver Disease
Clinical Gastroenterology and Hepatology, 2007, 5, 118-123
5.3103Citations (PDF)
367Factors Associated With Increased Survival After Photodynamic Therapy for Cholangiocarcinoma
Clinical Gastroenterology and Hepatology, 2007, 5, 743-748
5.371Citations (PDF)
368The Utility of Lens Culinaris Agglutinin-Reactive α-Fetoprotein in the Diagnosis of Hepatocellular Carcinoma: Evaluation in a United States Referral Population
Clinical Gastroenterology and Hepatology, 2007, 5, 394-402
5.3117Citations (PDF)
369Preliminary experience comparing routine cytology results with the composite results of digital image analysis and fluorescence in situ hybridization in patients undergoing EUS-guided FNA
Gastrointestinal Endoscopy, 2007, 66, 483-490
1.440Citations (PDF)
370Advanced Cytologic Techniques for the Detection of Malignant Pancreatobiliary Strictures
Gastroenterology, 2006, 131, 1064-1072
0.9312Citations (PDF)
371SULF1 Inhibits Tumor Growth and Potentiates the Effects of Histone Deacetylase Inhibitors in Hepatocellular Carcinoma
Gastroenterology, 2006, 130, 2130-2144
0.973Citations (PDF)
372Emerging drugs for hepatocellular carcinoma
Expert Opinion on Emerging Drugs, 2006, 11, 469-487
2.034Citations (PDF)
373A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells
Nature Medicine, 2006, 12, 410-416
22.8930Citations (PDF)
374Fiducial markers for MR histological correlation in ex vivo or short-term in vivo animal experiments: A screening study
Journal of Magnetic Resonance Imaging, 2006, 23, 50-59
2.614Citations (PDF)
375Hepatocellular Carcinoma: Molecular Pathways and New Therapeutic Targets
Seminars in Liver Disease, 2005, 25, 212-225
2.0271Citations (PDF)
376Chemokines as Attractive Targets in Liver Carcinogenesis
American Journal of Gastroenterology, 2005, 100, 499-501
0.67Citations (PDF)
377The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma
Journal of Hepatology, 2005, 42, 760-777
7.4191Citations (PDF)
378MYH Y165C and G382D mutations in hepatocellular carcinoma and cholangiocarcinoma patients
Journal of Cancer Research and Clinical Oncology, 2005, 132, 159-162
1.815Citations (PDF)
379A Comparison of Routine Cytology and Fluorescence in situ Hybridization for the Detection of Malignant Bile Duct Strictures
American Journal of Gastroenterology, 2004, 99, 1675-1681
0.6355Citations (PDF)
380HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma
Oncogene, 2004, 23, 1439-1447
5.2135Citations (PDF)
381Parkin gene alterations in hepatocellular carcinoma
Genes Chromosomes and Cancer, 2004, 40, 85-96
1.6112Citations (PDF)
382hSulf1 sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling
Gastroenterology, 2004, 126, 231-248
0.9143Citations (PDF)
383Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers
Oncogene, 2003, 22, 3813-3820
5.2220Citations (PDF)
384A novel sulfatase promotes apoptosis of hepatocellular carcinoma cells by modulation of FGF signaling
Gastroenterology, 2003, 124, A742
0.90Citations (PDF)
385Primer on Medical Genomics Part VI: Genomics and Molecular Genetics in Clinical Practice
Mayo Clinic Proceedings, 2003, 78, 307-317
2.025Citations (PDF)
38667-Year-Old Man With Hepatitis C Infection and Abdominal Distention
Mayo Clinic Proceedings, 2003, 78, 217-220
2.00Citations (PDF)
387Loss of HSulf-1 Up-regulates Heparin-binding Growth Factor Signaling in Cancer
Journal of Biological Chemistry, 2003, 278, 23107-23117
1.3227Citations (PDF)
388Mutational spectrum of β-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas
Oncogene, 2002, 21, 4863-4871
5.2486Citations (PDF)
389AXIN1 and beta catenin gene mutations in human hepatocellular carcinoma
Gastroenterology, 2001, 120, A360
0.90Citations (PDF)
390Retinoic acid receptor gene expression in hepatocellular carcinoma
Gastroenterology, 2001, 120, A361
0.90Citations (PDF)
391The FRA16D common chromosomal fragile site co-localizes with a region of LOH on chromosome 16 in hepatocellular carcinoma
Gastroenterology, 2001, 120, A360-A361
0.90Citations (PDF)
392hMLH1 and hMSH2 expression in human hepatocellular carcinoma
International Journal of Oncology, 2001, ,
3.721Citations (PDF)
393The Characterization of the Common Fragile Site FRA16D and Its Involvement in Multiple Myeloma Translocations
Genomics, 2000, 69, 37-46
2.087Citations (PDF)
394Pathophysiology of Variceal Bleeding
Gastrointestinal Endoscopy Clinics of North America, 1999, 9, 167-174
1.013Citations (PDF)
395Cathepsins as effector proteases in hepatocyte apoptosis
Cell Biochemistry and Biophysics, 1999, 30, 71-88
1.6101Citations (PDF)
396Dysregulation of Apoptosis as a Mechanism of Liver Disease: An Overview
Seminars in Liver Disease, 1998, 18, 105-114
2.0163Citations (PDF)
397Cathepsin B contributes to bile salt-induced apoptosis of rat hepatocytes
Gastroenterology, 1997, 113, 1714-1726
0.9175Citations (PDF)
398Hepatocytes in the bile duct-ligated rat express Bcl-2
American Journal of Physiology - Renal Physiology, 1997, 272, G1587-G1593
1.843Citations (PDF)
399Ascites and Hepatorenal Syndrome: Pathophysiology and Management
Mayo Clinic Proceedings, 1996, 71, 874-881
2.040Citations (PDF)
400Pathophysiology and Treatment of Variceal Hemorrhage
Mayo Clinic Proceedings, 1996, 71, 973-983
2.011Citations (PDF)
401MELAS‐ and kearns‐sayre‐type with myopathy and autoimmune polyendocrinopahy
Annals of Neurology, 1996, 39, 761-766
4.758Citations (PDF)
402Pathophysiology and Treatment of Variceal Hemorrhage
Mayo Clinic Proceedings, 1996, 71, 973-983
2.049Citations (PDF)
403cDNA and amino-acid sequences and organization of the gene encoding the Bβ subunit of fibrinogen from Xenopus laevis
Gene, 1995, 160, 223-228
1.66Citations (PDF)
404Transcriptional regulation of the Xenopus laevis B.beta. fibrinogen subunit gene by glucocorticoids and hepatocyte nuclear factor 1: Analysis by transfection into primary liver cells
Biochemistry, 1993, 32, 11627-11637
1.814Citations (PDF)
405Coordinate transcriptional regulation of the three fibrinogen subunit genes by glucocorticoids in cultured primary liver cells from Xenopus laevis.
Endocrinology, 1993, 132, 2563-2570
1.913Citations (PDF)
406Coordinate transcriptional regulation of the three fibrinogen subunit genes by glucocorticoids in cultured primary liver cells from Xenopus laevis
Endocrinology, 1993, 132, 2563-2570
1.93Citations (PDF)
407Molecular cloning of cDNA for the Bβ subunit of Xenopus fibrinogen, the product of a coordinately-regulated gene family
Molecular and Cellular Endocrinology, 1991, 75, 111-121
2.06Citations (PDF)
408Title is missing!
0
1Citations (PDF)
409Title is missing!
0
2Citations (PDF)
410Associations of S-Adenosylmethionine and S-Adenosylhomocysteine with Hepatocellular Carcinoma
Metabolites, 0, 15, 740
2.65Citations (PDF)
411Establishing cancer registries in Africa — focus on hepatopancreatobiliary cancers
Nature Reviews Gastroenterology and Hepatology, 0, 23, 189-200
31.12Citations (PDF)
412Low serum pseudocholinesterase levels are associated with mortality in patients with hepatocellular carcinoma
Hepatology Communications, 0, 10,
3.31Citations (PDF)
413Abstract 2682: Multiomic dissection of HBV-, HCV-, and non-viral HCC reveals distinct proliferation, interferon, and metabolic signatures.
Cancer Research, 0, 86, 2682-2682
4.20Citations (PDF)
414Abstract 3606: Identification of survival-associated germline variants in hepatocellular carcinoma
Cancer Research, 0, 86, 3606-3606
4.20Citations (PDF)
415941 EXPLORING THE IMPACT OF TUMOR GENOMICS ON SURVIVAL PREDICTION IN INTRAHEPATIC CHOLANGIOCARCINOMA: INSIGHTS AND LIMITATIONS
Gastroenterology, 0, 170, S-1404-S-1405
0.90Citations (PDF)
416Sul998 HEPATITIS C BURDEN IN AFRICA FROM 1990-2023: A COMPREHENSIVE ANALYSIS OF SEX-SPECIFIC TRENDS
Gastrointestinal Endoscopy, 0, 103, S-1512
1.40Citations (PDF)
4171255 THE NATIONAL RESPONSE TO HEPATITIS C IN GHANA: A TWO-PHASE KAP STUDY GUIDING AND GAUGING THE EDUCATIONAL IMPACT.
Gastrointestinal Endoscopy, 0, 103, S-1417
1.40Citations (PDF)
418941 EXPLORING THE IMPACT OF TUMOR GENOMICS ON SURVIVAL PREDICTION IN INTRAHEPATIC CHOLANGIOCARCINOMA: INSIGHTS AND LIMITATIONS
Gastrointestinal Endoscopy, 0, 103, S-1404-S-1405
1.40Citations (PDF)
419Sul998 HEPATITIS C BURDEN IN AFRICA FROM 1990-2023: A COMPREHENSIVE ANALYSIS OF SEX-SPECIFIC TRENDS
Gastroenterology, 0, 170, S-1512
0.90Citations (PDF)
4201255 THE NATIONAL RESPONSE TO HEPATITIS C IN GHANA: A TWO-PHASE KAP STUDY GUIDING AND GAUGING THE EDUCATIONAL IMPACT.
Gastroenterology, 0, 170, S-1417
0.90Citations (PDF)
421444 Exploiting global viral immunity to develop a novel viro-immunotherapy using oncolytic viruses and CAR T-cells for hepatocellular carcinoma
Journal of Clinical and Translational Science, 0, 10, 141-141
0.00Citations (PDF)
422366 Predicting survival in patients with neuroendocrine prostate cancer
Journal of Clinical and Translational Science, 0, 10, 119-119
0.00Citations (PDF)
423125 Hepatocellular carcinoma etiology and incidence in a midwestern population-based cohort, 2010-2021
Journal of Clinical and Translational Science, 0, 10, 38-39
0.00Citations (PDF)
42427Novel blood metabolomic tests for the diagnosis of Primary Sclerosing Cholangitis and associated Cholangiocarcinoma
Oncologist, 0, 31,
2.40Citations (PDF)
4252Development of a polygenic risk score to predict recurrence and survival in patients with resected cholangiocarcinoma
Oncologist, 0, 31,
2.40Citations (PDF)
426Multi-ancestry genome-wide association meta-analysis of hepatocellular carcinoma identifies 15 risk loci including MAP3K9, DHRS1, MTTP, and 8q24.21
Human Genetics and Genomics Advances, 0, 7, 100639
0.80Citations (PDF)
427Molecular Subtypes of Cholangiocarcinoma and Their Translational Implications
Gastroenterology, 0, ,
0.90Citations (PDF)